INDP Stock Price, Indaptus Therapeutics, . Quote, Chart

Market Summary

USD2.16+0.04

Delayedas of 30 Apr 2024, 01:29 pm

1.89%

INDP Stock Price

View Fullscreen

INDP RSI Chart

INDP Valuation

Market Cap

18.1M

Price/Earnings (Trailing)

-1.17

EV/EBITDA

-0.27

Price/Free Cashflow

-1.35

MarketCap/EBT

-1.22

INDP Price/Sales (Trailing)

INDP Profitability

Return on Equity

-127.71%

Return on Assets

-103.35%

Free Cashflow Yield

-74.05%

INDP Fundamentals

INDP Earnings

Earnings (TTM)

-15.4M

Earnings Growth (Yr)

-9.49%

Earnings Growth (Qtr)

-2.05%

Breaking Down INDP Revenue

52 Week Range

2.23

(Low)(High)

Last 7 days

-13.1%

Last 30 days

-5.4%

Last 90 days

27.0%

How does INDP drawdown profile look like?

INDP Financial Health

Current Ratio

5.05

INDP Investor Care

Shares Dilution (1Y)

1.72%

Diluted EPS (TTM)

-1.77

Tracking the Latest Insider Buys and Sells of Indaptus Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 14, 2023	anderson glen r.	bought	56,005	2.34	23,934	-
Aug 11, 2023	anderson glen r.	bought	74,335	2.12	35,064	-
Aug 10, 2023	anderson glen r.	bought	86,046	1.94	44,354	-
Dec 01, 2022	litchev boyan vesselinov	bought	935	1.8709	500	chief medical officer
Nov 22, 2022	litchev boyan vesselinov	bought	915	1.83	500	chief medical officer
Nov 21, 2022	meckler jeffrey a	bought	18,240	1.9	9,600	ceo and director
Nov 18, 2022	meckler jeffrey a	bought	705	1.7637	400	ceo and director
Sep 08, 2022	meckler jeffrey a	bought	28,862	2.8	10,308	ceo and director
Sep 07, 2022	meckler jeffrey a	bought	22,184	2.57	8,632	ceo and director
Sep 07, 2022	linscott walt addison	bought	393	2.62	150	chief business officer

Which funds bought or sold INDP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	STRATEGY ASSET MANAGERS LLC	unchanged	-	21,762	101,553	0.02%
Apr 11, 2024	Bangor Savings Bank	unchanged	-	192	896	-%
Mar 11, 2024	VANGUARD GROUP INC	added	2.2	-239,785	451,026	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	29,237	29,237	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-18,500	34,467	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	unchanged	-	-7.00	12.00	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	new	-	5.00	5.00	-%
Feb 14, 2024	Pine Valley Investments Ltd Liability Co	unchanged	-	-44,019	77,863	0.01%
Feb 14, 2024	Vivaldi Capital Management LP	unchanged	-	-26,083	40,037	0.01%
Feb 14, 2024	Royal Bank of Canada	new	-	-	-	-%

Are Funds Buying or Selling INDP?

Are funds buying INDP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own INDP

No. of Funds

Recent SEC filings of Indaptus Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Mar 25, 2024	8-K	Current Report
Mar 13, 2024	8-K	Current Report
Mar 13, 2024	424B5	Prospectus Filed
Mar 13, 2024	10-K	Annual Report
Mar 04, 2024	8-K	Current Report
Jan 23, 2024	8-K	Current Report
Jan 23, 2024	4	Insider Trading
Jan 23, 2024	4	Insider Trading

Peers (Alternatives to Indaptus Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

Indaptus Therapeutics, Inc. News

Latest updates

Indaptus Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-16.1%	15.00	18.00	21.00	23.00	28.00	30.00	34.00	37.00	41.00	44.00	20.00	17.00	2.00	21.00
Current Assets	-16.9%	14.00	17.00	20.00	22.00	27.00	30.00	33.00	37.00	40.00	44.00	19.00	12.00	2.00	14.00
Cash Equivalents	-16.3%	13.00	16.00	13.00	7.00	10.00	7.00	14.00	33.00	39.00	42.00	17.00	10.00	2.00	9.00
Net PPE	-30.3%	735*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	1.00	0.00	3.00
Liabilities	15.7%	3.00	2.00	2.00	2.00	3.00	3.00	4.00	4.00	5.00	-	6.00	6.00	2.00	10.00
Current Liabilities	17.3%	3.00	2.00	2.00	2.00	3.00	3.00	4.00	4.00	5.00	6.00	5.00	5.00	2.00	8.00
Shareholder's Equity	-21.2%	12.00	15.00	19.00	21.00	25.00	28.00	30.00	33.00	36.00	38.00	14.00	11.00	15.00	3.00
Retained Earnings	-9.7%	-45.42	-41.40	-37.49	-34.20	-29.99	-26.30	-22.90	-19.04	-15.67	-12.45	-215	-207	-7.96	-189
Additional Paid-In Capital	1.3%	57.00	57.00	56.00	55.00	54.00	54.00	53.00	52.00	51.00	50.00	228	218	8.00	200
Shares Outstanding	0%	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	3.00	2.00	2.00	2.00	-
Float	-	-	-	13.00	-	-	-	15.00	-	-	-	26.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	29.7%	-2,601	-3,703	-2,137	-4,962	-2,210	-4,601	-3,148	-3,117	-3,539	-5,630	-1,294	-825	-957	4,449	-1,670	-5,147	-
Share Based Compensation	-2.5%	746	765	728	727	638	584	904	831	674	795	21.00	20.00	23.00	-739	414	442	-
Cashflow From Investing	-100.0%	-	7,000	8,000	2,141	5,120	-2,939	-15,809	-2,798	452	-1.65	-1.20	-1.00	-	-	-	769	-
Cashflow From Financing	-	-	-	-	-	-	-	-	-	363	42,524	1,775	3,675	-3.96	-9,436	4,491	6,113	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

INDP Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 7,621,707	$ 6,324,657
General and administrative	8,756,767	8,586,249
Total operating expenses	16,378,474	14,910,906
Loss from operations	(16,378,474)	(14,910,906)
Other income, net	955,003	588,108
Net loss	$ (15,423,471)	$ (14,322,798)
Net loss available to common stockholders per share of common stock, basic	$ (1.83)	$ (1.73)
Net loss available to common stockholders per share of common stock, diluted	$ (1.83)	$ (1.73)
Weighted average number of shares used in calculating net loss per share, basic	8,401,047	8,262,119
Weighted average number of shares used in calculating net loss per share,diluted	8,401,047	8,262,119
Other comprehensive income:
Reclassification adjustment for interest earned on marketable securities included in net loss	$ (430,993)	$ (110,002)
Change in unrealized gain on marketable securities	334,559	206,436
Comprehensive loss	$ (15,519,905)	$ (14,226,364)

INDP Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 13,362,053	$ 9,626,800
Marketable securities		16,806,009
Prepaid expenses and other current assets	633,156	811,433
Total current assets	13,995,209	27,244,242
Non-current assets:
Property and equipment, net	735	2,019
Right-of-use asset	173,206	79,294
Other assets	754,728	738,251
Total non-current assets	928,669	819,564
Total assets	14,923,878	28,063,806
Current liabilities:
Accounts payable and other current liabilities	2,672,327	3,352,847
Operating lease liability, current portion	101,705	80,494
Total current liabilities	2,774,032	3,433,341
Non-current liabilities:
Operating lease liability, net of current portion	73,348
Total non-current liabilities	73,348
Total liabilities	2,847,380	3,433,341
Commitments and contingencies (Note 8)
Stockholders’ equity:
Common stock: $0.01 par value, 200,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 8,401,047 shares issued and outstanding as of December 31, 2023 and December 31, 2022	84,011	84,011
Additional paid in capital	57,409,643	54,443,705
Accumulated deficit	(45,417,156)	(29,993,685)
Accumulated other comprehensive income		96,434
Total stockholders’ equity	12,076,498	24,630,465
Total liabilities and stockholders’ equity	$ 14,923,878	$ 28,063,806

About Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

CEO	Mr. Jeffrey A. Meckler
WEBSITE	https://indaptusrx.com
INDUSTRY	Biotechnology
EMPLOYEES	6

Indaptus Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Indaptus Therapeutics, Inc.? What does INDP stand for in stocks?

INDP is the stock ticker symbol of Indaptus Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Indaptus Therapeutics, Inc. (INDP)?

As of Mon Apr 29 2024, market cap of Indaptus Therapeutics, Inc. is 18.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INDP stock?

You can check INDP's fair value in chart for subscribers.

What is the fair value of INDP stock?

You can check INDP's fair value in chart for subscribers. The fair value of Indaptus Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Indaptus Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INDP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Indaptus Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether INDP is over valued or under valued. Whether Indaptus Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Indaptus Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INDP.